Development of vaccines against influenza H5

被引：39
作者：
Stephenson, Iain [1 ]
Gust, Ian
Pervikov, Yuri
Kieny, Marie Paule
机构：
[1] Univ Hosp Leicester, Infect Dis Unit, Leicester Royal Infirm, Leicester, Leics, England
[2] WHO, Collaborating Ctr Influenza Reference & Res Melbo, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3052, Australia
[4] WHO, Inst Vaccine Res, CH-1211 Geneva, Switzerland
来源：
LANCET INFECTIOUS DISEASES | 2006年 / 6卷 / 08期
关键词：
D O I：
10.1016/S1473-3099(06)70528-X
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：458 / 460
页数：3
相关论文
共 9 条
  • [1] Aubin JT, 2005, EMERG INFECT DIS, V11, P1515
  • [2] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
    Bresson, Jean-Louis
    Perronne, Christian
    Launay, Odile
    Gerdil, Catherine
    Saville, Melanie
    Wood, John
    Hoeschler, Katja
    Zambon, Maria C.
    [J]. LANCET, 2006, 367 (9523) : 1657 - 1664
  • [3] Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model
    Lipatov, AS
    Webby, RJ
    Govorkova, EA
    Krauss, S
    Webster, RG
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) : 1216 - 1220
  • [4] Development and evaluation of influenza pandemic vaccines
    Stephenson, I
    Gust, I
    Kieny, MP
    Pervikov, Y
    [J]. LANCET INFECTIOUS DISEASES, 2006, 6 (02) : 71 - 72
  • [5] Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
    Stephenson, I
    Bugarini, R
    Nicholson, KG
    Podda, A
    Wood, JM
    Zambon, MC
    Katz, JM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (08) : 1210 - 1215
  • [6] Confronting the avian influenza threat: vaccine development for a potential pandemic
    Stephenson, I
    Nicholson, KG
    Wood, JM
    Zambon, MC
    Katz, JM
    [J]. LANCET INFECTIOUS DISEASES, 2004, 4 (08) : 499 - 509
  • [7] Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
    Treanor, JJ
    Campbell, JD
    Zangwill, KM
    Rowe, T
    Wolff, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (13) : 1343 - 1351
  • [8] Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines
    Webby, RJ
    Perez, DR
    Coleman, JS
    Guan, Y
    Knight, JH
    Govorkova, EA
    McClain-Moss, LR
    Peiris, JS
    Rehg, JE
    Tuomanen, EI
    Webster, RG
    [J]. LANCET, 2004, 363 (9415) : 1099 - 1103
  • [9] *WHO, 2006, AV INFL
1